Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia – 1/22/2024
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 – 12/10/2024
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH – 12/10/2024
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors – 12/3/2024
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI – 12/19/2024
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD) – 11/15/2024
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma – 11/12/2024
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy- 11/12/2024
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates – 11/11/2024
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors – 11/7/2024
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results – 11/7/2024
OncoResponse Announces Phase 1 results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer- 11/7/2024
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors- 10/10/2024
InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance – 10/7/2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million – 10/4/2024
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia – 9/18/2024
Glycomine Receives FDA Fast Track Designation for BLM101 for the Treatment of PMM2-CDG- 9/18/2024
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis – 9/3/2024
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Noval Inhaled Nintedanib – 8/12/2024
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors- 8/8/2024
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors- 8/5/2024
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older – 7/25/2024
Integrated DNA Technologies Announces New Licensing Agreement with SeQure Dx to Advance CRISPR-based Therapeutics – 7/15/2024
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC – 7/8/2024
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies – 6/17/2024
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress – 6/14/2024
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress – 6/5/2024
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D – 5/29/2024
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
– 5/20/2024
Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
– 4/4/2024
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection- 3/25/2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies – 3/19/2024
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis – 3/14/2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG – 3/4/2024
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers – 1/23/2024
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia – 1/22/2024
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting – 12/11/2023
VentureMed Receives Transitional Pass-through Payment (TPT) for FLEX Vessel Prep™ System – 11/8/2023
Spruce Biosciences Completes Target Enrollment of Cahmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia – 10/18/2023
Reneo Pharmaceuticals Announces Last Patient Last visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) – 10/9/2023
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies – 9/27/2023
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics – 9/5/2023
Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refactory (R/R) Acute Myeloid Leukemia (AML) – 8/15/2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results 8/14/2023
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results 8/10/2023
Allakos provides Business Update and Reports Second Quarter 2023 Financial Results 8/9/2023
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update 8/3/2023
Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan 6/20/2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at European Hematology Association (EHA) 2023 Congress 6/9/2023
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment 6/1/2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 5/25/2023
OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy 5/18/2023
Reports First Quarter 2023 Financial Results and Provides Corporate Updates – 5/15/2023
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results 5/11/2023
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors – 5/10/2023
Provides Business Update and Reports First Quarter 2023 Financial Results – 5/9/2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results – 5/9/2023
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update – 5/4/2023
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock – 5/3/2023
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis– 4/11/2023
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors– 4/6/2023
Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023
Wugen, Inc. Announces CEO Transition — Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer – 3/21/2023
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023
Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 3/6/2023
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023
Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023
Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023
Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023
Miurm Pharmaceuticals‘ LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022
Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D – 12/1/2022
SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients – 11/16/2022
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies – 11/15/2022
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) – 10/24/2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer – 10/17/2022
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older – 10/14/2022
Teleflex Completes Acquisition of Standard Bariatrics – 9/28/2022
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche – 9/7/2022
Teleflex to Expand It’s Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery – Signs Definitive Agreement to Acquire Standard Bariatrics – 8/22/2022
Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis. – 8/16/2022
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – 8/4/2022
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results – 8/4/2022
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates – 7/27/2022
Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/RT-ALL/LBL 7/19/2022
Allakos, Inc. Provides Business Update and Reports First Quarter 2022 Financial Results – 5/6/2022
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update – 3/23/2022
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/RT-ALL/LBL, 3/15/2022
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates – 3/14/2022
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update – 3/9/2022
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results – 3/1/2022
Standard Bariatrics Achieves Final Series B Funding Early, 2/28/2022
Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse – 2/15/2022
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma – 1/21/2022
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors – 1/20/2021
Titan SGS from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses – 1/19/2022
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101 – 12/17/2021
InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA – 12/13/2021
Standard Bariatrics, Inc. Reaches Sales Milestone With Titan SGS™ – 12/13/2021
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma – 11/30/2021
Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection – 11/17/2021
Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment – 11/17/2021
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome – 11/15/2021
Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting – 11/12/2021
Scout Bio Named Best New Start-Up for 2021 – 11/08/2021
Biolinq raises $100 million for needle-free biosensors for diabetes monitoring – 11/2/2021
Xilio Therapeutics Announces Closing of Initial Public Offering – 10/26/2021
U.S. FDA Approves LIVMARLI (Maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older – 9/29/2021
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors – 9/16/2021
Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia – 9/9/2021
Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality – 8/17/2021
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates – 8/10/2021
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results – 8/9/2021
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update – 8/5/2021
SeQure Dx Announces $17.5M Series A Funding – 8/3/2021
Mirum Pharmaceuticals And GC Pharma Enter Into Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea – 7/26/2021
Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021
Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021
Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021
Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021
© Copyright RiverVest® All Rights Reserved.